• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Dicot Pharma

0.25 SEK

+6.68 %

Less than 1K followers

DICOT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+6.68 %
+8.07 %
-6.48 %
-7.70 %
-23.82 %
-49.40 %
+223.77 %
-41.80 %
-88.91 %

Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug for the treatment of erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are the main desired properties. Dicot's main strategy is to continuously evaluate industrial partnerships during the development of LIB-01 to take the drug candidate to commercialization. The company is based in Uppsala.

Read more
Market cap
819.26M SEK
Turnover
7.49M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/8
2026

Interim report Q2'26

28/10
2026

Interim report Q3'26

12/2
2027

Annual report '26

Regulatory press release5 hours ago

Dicot Pharma offentliggör slutgiltigt utfall i den övertecknade företrädesemissionen och genomför riktade emissioner

Dicot Pharma
Regulatory press release5 hours ago

Dicot Pharma announces final outcome in the oversubscribed rights issue and carries out directed share issues

Dicot Pharma
Press release6/5/2026, 8:00 AM

Dicot Pharma presenterar på Aktiespararnas event Aktiedagarna den 9 juni

Dicot Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release6/5/2026, 8:00 AM

Dicot Pharma presents at Aktiespararnas’ event Aktiedagarna on June 9

Dicot Pharma
Regulatory press release6/4/2026, 3:28 PM

Dicot Pharma offentliggör preliminärt utfall i övertecknad företrädesemission

Dicot Pharma
Regulatory press release6/4/2026, 3:28 PM

Dicot Pharma announces preliminary outcome in oversubscribed rights issue

Dicot Pharma
Press release6/1/2026, 8:45 AM

Dicot Pharma får nytt patent i Japan för LIB-01

Dicot Pharma
Press release6/1/2026, 8:45 AM

Dicot Pharma receives patent approval in Japan for LIB-01

Dicot Pharma
Regulatory press release5/29/2026, 6:00 AM

Dicot Pharma informerar om sista dag för teckning av units i pågående företrädesemission

Dicot Pharma
Regulatory press release5/29/2026, 6:00 AM

Dicot Pharma announces the final subscription date for units in the ongoing rights issue

Dicot Pharma
Regulatory press release5/27/2026, 6:05 AM

Dicot Pharma har erhållit avsiktsförklaringar om cirka 15,6 miljoner kronor från befintliga aktieägare i den pågående företrädesemissionen

Dicot Pharma
Regulatory press release5/27/2026, 6:05 AM

Dicot Pharma receives indications of interest for approx. SEK 15.6 million from existing shareholders in the ongoing rights issue

Dicot Pharma
Press release5/25/2026, 10:35 AM

Dicot Pharma har lämnat in IND-ansökan till FDA

Dicot Pharma
Press release5/25/2026, 10:35 AM

Dicot Pharma submits an IND application to the FDA

Dicot Pharma
Press release5/22/2026, 7:45 AM

Dicot Pharma bjuder in till livesänd bolagspresentation och frågestund 27 maj

Dicot Pharma
Press release5/22/2026, 7:45 AM

Dicot Pharma Invites to a live company presentation and Q&A session in Swedish on May 27

Dicot Pharma
Regulatory press release5/21/2026, 6:00 AM

Idag inleds teckningsperioden i Dicot Pharmas företrädesemission

Dicot Pharma
Regulatory press release5/21/2026, 6:00 AM

The subscription period in Dicot Pharma’s rights issue commences today

Dicot Pharma
Press release5/20/2026, 8:30 AM

Dicot Pharma slutför tillverkning av tabletter inför fas 2b-studie

Dicot Pharma
Press release5/20/2026, 8:30 AM

Dicot Pharma completes tablet manufacturing ahead of phase 2b clinical study

Dicot Pharma